Abstract
BackgroundΑim of the study was to determine the effect of mirabegron, used for overactive bladder (OAB) treatment, on female sexual function.MethodsEighty five sexually active women suffering from overactive bladder were prospectively enrolled in this study. Females were divided into two groups. In Group A (control), 48 patients received no treatment and in Group B, 37 patients received mirabegron 50 mg/daily for 3 months. Patients were evaluated with FSFI-Gr at the beginning of the study and again after a period of 3 months.ResultsIn Group B, there was a significant increase post-treatment compared to baseline (p < 0.001) in total FSFI (20.3 (3.8) to 26.6 (4.2)) and all domains (desire: 3.0 (1.2) to 4.8 (1.2)), arousal: 3.0 (0.8) to 4.8 (0.9), lubrication: 3.9 (1.1) to 4.8 (1.2), orgasm: 3.6 (0.8) to 4.8 (1.0), satisfaction: 3.2 (0.4) to 4.0 (0.8) and pain: 3.2 (0.8) to 4.4 (1.2)). In Group A, there were no statistically significant changes in pre- and post-observation values.ConclusionsThis study is one of the few demonstrating that management of OAB with mirabegron improves female sexual function.Trial registrationTRN ISRCTN17199301, 20/10/2017, retrospectively registered.
Highlights
Αim of the study was to determine the effect of mirabegron, used for overactive bladder (OAB) treatment, on female sexual function
The objective of the current study is to evaluate the effect of the β3-adrenoceptor agonist, mirabegron, as used for OAB treatment on the sexual function of women
Non-parametric tests (Mann Whitney U test and Wilcoxon signed-rank test, respectively) were performed for all comparisons between and within groups, respectively; all data are presented as medians
Summary
Αim of the study was to determine the effect of mirabegron, used for overactive bladder (OAB) treatment, on female sexual function. Overactive bladder (OAB) is defined by the International Continence Society (ICS) as urinary urgency in the absence of any known infection or other obvious pathology. OAB is usually characterized by frequency and nocturia, but may or may not cause urinary incontinence [1]. OAB is a debilitating disease which can substantially impede the quality of life, Female sexual dysfunction (FSD) is traditionally classified into disorders of desire, arousal, lubrication, orgasm and pain. In the absence of detailed epidemiological data, current estimates have up to 43% of women complaining of at least one sexual issue [10]. Lower tract urinary tract infections are a further, independent FSD cause [10, 11]. The Female Sexual Function Index (FSFI) is a concise, multidimensional “gold standard” tool which is regarded in high-esteem [12]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
